Business and Intellectual Capital Development in Financial Riptide - Case Studies of Finnish Biotechnology and Pharmaceutical Companies Dispersing into Global Value Chains
This study focused on two primary areas: 1. To determine what can be learned from biotech and drug development companies that suffered from financial problems and ultimately failed at the beginning of the 21st century. 2. To determine how intellectual capital developed in accordance with such companies and its fate following business failure. We examined six failed Finnish biotechnology companies and two major venture capital companies that have invested in Finnish biotechnology companies. We strongly emphasize that this research is only a case-based and very limited feasibility study. Nevertheless, the results were surprising. We found that intellectual capital was indeed created in the companies and that various aspects of this capital could be identified. To a certain extent, we were also able to follow the post-company steps of intellectual capital and the continuity of its value-creation in novel companies. The study was designed to involve only failed companies, but in four cases we found ourselves interviewing leaders of companies that had been created based on the IC of failed companies. It appears that important knowledge has vested by learning from earlier mistakes, and this learning period has created important intellectual capital that has already been exploited by various companies. Research-intensive companies typically operate in fields where failure is an inherent risk. Governments typically support emerging industries based on high-technology because of their growth potential. The combination of high-intensity R&D and high risks creates a problem for all investors. The created value is primarily in the form of intangible assets, which are not captured in traditional accounting and for which no well-established alternative metrics exist. Consequently, in the case of a company failure, most of the created value added is considered lost. This loss not only complicates the justification of government support policies but typically leads to high initial expectations of the sector that are unfortunately often followed by subsequent disappointments. We think that the present concept of failure may be profoundly misleading.
|Date of creation:||15 Oct 2013|
|Date of revision:|
|Contact details of provider:|| Postal: Lönnrotinkatu 4 B, FIN-00120 HELSINKI|
Phone: +358 (0)9 609 900
Fax: +358 (0)9 601 753
Web page: http://www.etla.fi/
More information through EDIRC
|Order Information:|| Email: |
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Nikulainen, Tuomo & Tahvanainen, Antti-Jussi & Kulvik, Martti, 2012. "Expectations, Reality and Performance in the Finnish Biotechnology Business," Discussion Papers 1286, The Research Institute of the Finnish Economy.
- Hoetker, Glenn & Agarwal, Rajshree, 2005. "Death Hurts, But It Isn't Fatal: The Postexit Diffusion of Knowledge Created by Innovative Companies," Working Papers 05-0100, University of Illinois at Urbana-Champaign, College of Business.
- Hyytinen, Ari & Määttänen, Niku & Lassila, Jukka & Valkonen, Tarmo, 2010. "Eläkevaroilla vauhtia Suomen talouskasvuun?," Discussion Papers 1224, The Research Institute of the Finnish Economy.
When requesting a correction, please mention this item's handle: RePEc:rif:report:17. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Kaija Hyvönen-Rajecki)
If references are entirely missing, you can add them using this form.